



Article Asperinsuterpenes A–C from the Fungus Aspergillus insuetus BTBU20220155

Xinjun Zhang¹, Fuhang Song^{2,*}, Jiahui Han³, Long Wang⁴, Linlin Ma⁵ and Xiuli Xu³

- Key Laboratory of Forest Ecology in Tibet Plateau (Ministry of Education), Institute of Tibet Plateau Ecology, Tibet Agriculture & Animal Husbandry University, Nyingchi 860000, China; zxjun_126abc@126.com
- ² Key Laboratory of Geriatric Nutrition and Health, Ministry of Education of China, School of Light Industry Science and Engineering, Beijing Technology and Business University, Beijing 100048, China
- ³ Key Laboratory of Polar Geology and Marine Mineral Resources, Ministry of Education, School of Ocean Sciences, China University of Geosciences, Beijing 100083, China; 15632779760@163.com (J.H.)
- ⁴ State Key Lab of Mycology, Institute of Microbiology, Chinese Academy of Sciences, Beijing 100101, China; wl_dgk@im.ac.cn
- ⁵ Institute for Biomedicine and Glycomics, School of Environment and Science, Griffith University, Brisbane, QLD 4111, Australia
- * Correspondence: songfuhang@btbu.edu.cn

Abstract: Three new meroterpenoids, asperinsuterpenes A–C (1–3), and eight previously reported natural products, namely asnovolin I (4), (2'*E*,4'*E*,6'*E*)-6-(1'-carboxyocta-2',4',6'-triene)-9-hydroxydrim-7-ene-11,12-olide (5), (2'*E*,4'*E*,6'*E*)-6-(1'-carboxyocta-2',4',6'-triene)-11,12-epoxy-9,11-dihydroxydrim-7-ene (6), cinereain (7), carnequinazolines A and B (8 and 9), carnemycin B (10), and stromemycin (11) were isolated from the fungus *Aspergillus insuetus*, strain BTBU20220155. The structures of the compounds were determined based on spectroscopic techniques, including 1D and 2D NMR, HRES-IMS, and ECD experiments. The in vitro antimicrobial evaluation revealed that compounds **5** and **11** exhibited inhibitory activity against *Candida albicans*, with minimum inhibitory concentration (MIC) values of 12.5 and 25 μ g/mL, respectively. These findings suggest that *A. insuetus* is a promising source of bioactive natural products with potential applications in antifungal therapy.

Keywords: Aspergillus insuetus; Tibet; spiromeroterpenoid; Candida albicans

1. Introduction

Fungi have long been recognized as a vital source of structurally and biologically significant natural products, including penicillin, cyclosporin A, and lovastatin. Among fungi, *Aspergillus* species, which thrive in diverse environments such as soil, leaves, water, marine settings, and decaying food, are particularly noteworthy. Numerous bioactive compounds, such as heterocyclic alkaloids, sesquiterpenoids, polyketides, and pyrones, have been identified from *Aspergillus* fungi [1–4].

Aspergillus insuetus, belonging to the *Aspergillus* section Usti, was first described in 1929 [5]. This filamentous fungus is found in various environments, such as soil, foods, indoor air, and samples collected from marine environments [5,6]. Chemical investigations of *A. insuetus* have revealed numerous compounds with diverse bioactivates, including drimane sesquiterpenes [6–9], phenol derivatives [10], meroterpenoids, and depsipeptides [11].

As part of our ongoing screening of active natural products from fungi, we isolated a strain of *A. insuetus* BTBU20220155 from a soil sample collected from the Sejila Mountain, Tibet, China. To diversify the new chemical entries from *A. insuetus*, a systematic chemical investigation of *A. insuetus* BTBU20220155 was performed, which led to the identification of three new compounds **1–3**, along with eight previously reported compounds from other fungal sources, including drimane sesquiterpene esters, asnovolin I (4), (2'E,4'E,6'E)-6-(1'-carboxyocta-2',4',6'-triene)-9-hydroxydrim-7-ene-11,12-olide



Citation: Zhang, X.; Song, F.; Han, J.; Wang, L.; Ma, L.; Xu, X. Asperinsuterpenes A–C from the Fungus *Aspergillus insuetus* BTBU20220155. *J. Fungi* 2024, *10*, 611. https://doi.org/10.3390/jof10090611

Academic Editors: Carlos García-Estrada, Inmaculada Vaca and Renato Chávez

Received: 8 July 2024 Revised: 11 August 2024 Accepted: 23 August 2024 Published: 27 August 2024



Copyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/). (5), (2'*E*,4'*E*,6'*E*)-6-(1'-carboxyocta-2',4',6'-triene)-11,12-epoxy-9,11-dihydroxydrim-7-ene (6) [12], cinereain (7) [13], carnequinazolines A and B (8 and 9), carnemycin B (10), [14], and stromemycin (11) [15,16]. The isolated compounds were evaluated for their in vitro antifungal and antibacterial activities against *Candida albicans*, *Staphylococcus aureus*, and *Escherichia coli*, respectively. Herein, we present the fermentation, compound isolation, structural characterization, and bioactivity evaluation of the isolated compounds.

2. Materials and Methods

2.1. Molecular Identification

The fungus *A. insuetus* BTBU20220155 was isolated from a soil sample collected from Sejila Mountain, Tibet, China. This strain was cultured on a potato dextrose agar plate for 7 days at 28 °C. The genomic DNA of *A. insuetus* BTBU20220155 was extracted using a Fungi Genomic DNA Kit (Solarbio, Beijing, China), and the internal transcribed spacer (ITS) region was amplified using the conventional primer pair of ITS5 (5'-GGAAGTAAAAGTCGTAAC-AAGG-3') and ITS4 (5'-TCCTCCGCTTATTGATATGC-3'). Then, the sequence of PCR products was determined by Beijing Qingke Biotechnology Co., Ltd. (Beijing, China). The ITS sequence of strain BTBU20220155 was compared against the GenBank database using the BLAST program. The Sequence similarity was determined using multiple sequence alignment with CLUSTAL W [17]. The strain has been deposited at Beijing Technology and Business University, Beijing, China, with the accession number BTBU20220155.

2.2. General Experimental Procedure

The optical rotations ($[\alpha]_D$) were determined using an Anton Paar MCP 200 Modular Circular Polarimeter (Graz, Austria). The circular dichroism (CD) spectra were recorded on an Applied Photophysics Chirascan spectropolarimeter (Surrey, UK). The NMR spectra were obtained on a Bruker Avance 500 spectrometer (Fällanden, Switzerland), with residual solvent peaks as references (Acetone- d_6 : δ_H 2.05, δ_C 28.4). High-resolution ESIMS measurements were obtained on an Accurate-Mass-Q-TOF LC/MS 6520 instrument (Santa Clara, CA, USA). HPLC was performed using an Agilent 1200 Series separation module with a diode array detector (Santa Clara, CA, USA), 1260 Series fraction collector, and Agilent XDB-C8, RX-C8, and XDB-C18 columns (250 × 9.4 mm, 5 µm).

2.3. Fungal Materials, Cultivation, Fermentation, and Isolation

A. insuetus BTBU20220155 was cultured on potato dextrose agar (Solarbio, Beijing, China) at 28 °C for 7 days. Small sections (approximately 1 cm²) were inoculated into 1 L conical flasks (\times 15), each containing 150 mL of distilled water and 200 g of rice (Taiyuxiang, COFCO, Beijing, China). The flasks were incubated stationary at 28 °C for 24 days. The cultured medium with fungi was extracted using a mixture of EtOAc:MeOH (80:20). The whole culture and extraction procedure was repeated three times, and the combined extracts were concentrated to dryness in vacuum, producing a thick liquid, which is usually referred to as a dark residue. The residue was partitioned between EtOAc and H₂O. Then, the EtOAc was removed in vacuo to yield a dark residue (5.63 g).

The EtOAc fraction was subjected to vacuum silica gel chromatography (50×80 mm column, TLC H silica), eluting with a stepwise gradient of 50–100% hexane/CH₂Cl₂ and then 100–10% CH₂Cl₂/MeOH, resulting in 10 fractions. Fraction M was further purified on a Sephadex LH-20 column (600×30 mm), eluting with an isocratic elution with CH₂Cl₂:MeOH (2:1), yielding six subfractions (F1–F6). Subfraction F1 was further fractionated by HPLC (Agilent Eclipse XDB-C8, 250×9.4 mm, 5μ m column, 3.0 mL/min, isocratic 45% MeCN/H₂O with isocratic 0.01% TFA modifier) to yield compound **1** (t_R 11.836 min, 11.5 mg). Subfraction F2 was separated by HPLC (Agilent Eclipse XDB-C8, 250×9.4 mm, 5μ m column, 3.0 mL/min, isocratic 45% MeCN/H₂O with isocratic 0.01% TFA modifier) to yield F2-1, F2-2, F2-3 and F2-4, respectively. F2-3 was further fractionated by HPLC (Agilent Eclipse XDB-C8, 250×9.4 mm, 5μ m column, 3.0 mL/min, isocratic 50% MeCN/H₂O) to give compound **2** (t_R 11.453 min, 10.7 mg), compound **4**

(t_R 11.453 min, 26.2 mg) and compound **3** (t_R 11.618 min, 8.1 mg). Subfraction F4 was subjected to HPLC (Agilent Zorbax RX-C8, 250 × 9.4 mm, 5 µm column, 3.0 mL/min, gradient elution from 30 to 100% MeCN/H₂O over 30 min) to yield compound **8** (t_R 10.795 min, 5.3 mg), compound **7** (t_R 10.957 min, 7.6 mg), compound **9** (t_R 11.313 min, 3.4 mg), compound **5** (t_R 13.083 min, 5.3 mg), and compound **6** (t_R 13.847 min, 24.8 mg), respectively. Fraction Q was separated on a Sephadex LH-20 column (600 × 30 mm) using an isocratic elution with CH₂Cl₂:MeOH (2:1), to give five subfractions (F1–F5). Subfraction F4 was subjected to column chromatographic separation by HPLC (Agilent Eclipse XDB-C18, 250 × 9.4 mm, 5 µm column, 3.0 mL/min, gradient elution from 45–70% MeCN/H₂O over 25 min with isocratic 0.01% TFA modifier) to yield compound **10** (t_R 12.470 min, 59.5 mg) and compound **11** (t_R 10.183 min, 10.5 mg).

Asperinsuterpene A (1): Colorless amorphous powder; $[\alpha]_D^{22}$ + 154 (MeOH, 0.1); (+)-HRESIMS *m*/*z* 441.2273 [M + H]⁺ (calcd. for C₂₆H₃₂O₆ 441.2272); ¹H and ¹³C NMR data: See Table 1.

Position	1		2	
	$\delta_{\rm C}$	$\delta_{\mathrm{H}_{\prime}}$ (J in Hz)	δ_{C}	$\delta_{ m H}$, (J in Hz)
1	148.5, CH	6.32, d (13.0)	35.2, CH ₂	2.07, m; 2.00, m
2	121.7, CH	5.90, d (13.0)	30.3, CH ₂	2.44, m
3	166.0, C		174.6, C	
4	84.3, CH		74.8, C	
5	51.5, CH	2.16, dd (8.5, 6.5)	50.7, CH	1.73, m
6α	21.2, CH ₂	1.83, m	23.1, CH ₂	1.88, m
6β				1.66, m
7α	29.9, CH ₂	1.91, m	29.6, CH ₂	1.70 <i>,</i> m
7β		1.73, m		1.60, m
8	39.0, CH	2.12, m	37.4, CH	2.03, m
9	92.8, C		96.7, C	
10	51.5, C		46.4, C	
11α	44.5, CH ₂	3.31, dd (18.0, 2.0)	40.4, CH ₂	3.62, dd (19.0, 2.0)
11β		3.26, dd (18.0, 1.5)		3.20, dd (19.0, 2.0)
12	141.9, C		143.1, C	
13	131.2, CH	6.87, brs	130.0, CH	6.91, s
14	139.8, C		139.6, C	
15	143.6, C		143.4, C	
16	181.3, C		181.3, C	
17	127.8, C		126.3, C	
18	163.5, C		165.1, C	
19	23.9, CH ₃	2.14, s	23.9, CH ₃	2.15, s
20	169.2, C		169.2, C	
21	52.0, OCH ₃	3.78, s	51.9, OCH ₃	3.76, s
22	13.3, CH ₃	2.13, s	13.7, CH ₃	2.09, s
23	18.0, CH ₃	1.57, s	18.7, CH ₃	1.25, s
24	16.9, CH ₃	1.22, d (7.5)	16.7, CH ₃	0.88, d (7.0)
25α	32.1, CH ₃	1.41, s	28.9, CH ₃	1.31, s
26β	25.6, CH ₃	1.50, s	34.5, CH ₃	1.34, s
27			51.6, CH ₃	3.59, s
4-OH				3.45, s

Table 1. ¹H (500 MHz) and ¹³C (125 MHz) NMR data of **1** and **2** (Acetone-*d*₆).

Asperinsuterpene B (2): Colorless amorphous powder; $[\alpha]_D^{22}$ + 55 (MeOH, 0.1); (+)-HRESIMS *m*/*z* 497.2518 [M + Na]⁺ (calcd. for C₂₇H₃₈O₇Na 497.2510); ¹H and ¹³C NMR data: See Table 1.

Asperinsuterpene C (3): Colorless amorphous powder; $[\alpha]_D^{22}$ + 3 (MeOH, 0.1); (+)-HRESIMS *m*/*z* 445.2583 [M + H]⁺ (calcd. for C₂₆H₃₇O₆ 445.2585); ¹H and ¹³C NMR data: See Table 2.

	3		
Position	δ _C	$\delta_{ m H_{\prime}}$ (J in Hz)	
1a	33.2, CH ₂	1.91, m	
1b		1.82, m	
2a	32.8, CH ₂	2.74, m	
2b		2.68, ddd (15.0, 7.5, 4.0)	
3	173.9, C		
4	85.1, C		
5	50.0, CH	2.07, m	
6α	22.3, CH ₂	1.84, m	
6β		1.55, m,	
7α	29.9, CH ₂	1.83, m	
7β		1.51, m	
8	38.6, CH	1.85, m	
9	100.7, C		
10	44.4, C		
11α	37.5, CH ₂	2.35, d (13.5)	
11β		2.23, d (13.5)	
12	48.8, C		
13	156.1, C		
14	132.8, C		
15	184.2, C		
16	108.8, C		
17	179.8, C		
18	35.0, CH ₃	1.60, s	
19	16.8, CH ₃	2.05, s	
20	168.1, C		
21	52.0, OCH ₃	3.74, s	
22	8.1, CH ₃	1.75, s	
23	17.5, CH ₃	1.39, s	
24	16.6, CH ₃	0.94, d (6.5)	
25	32.3, CH ₃	1.45, s	
26	25.1, CH ₃	1.42, s	

Table 2. ¹H (500 MHz) and ¹³C (125 MHz) NMR data of 3 ((Acetone-*d*₆)).

2.4. ECD Calculation Methods

The ECD calculation was carried out using previously reported methods [18]. The conformers were submitted for geometric optimization at the level of CAM-B3LYP/6-31g(d) with the Gaussian 16 software package using the DFT method [19]. Excited state calculations of their low-energy conformations were performed using the TDDFT (time-dependent density functional theory) at the same level.

2.5. Antimicrobial Assay

The antimicrobial evaluations were carried out based on the Antimicrobial Susceptibility Testing Standards outlined by the Clinical and Laboratory Standards Institute (CLSI) against *S. aureus* (ATCC 6538), *E. coli* (ATCC 11775), and *C. albicans* (ATCC 10231), using a 96-well plate microdilution method. Briefly, the bacterial strains were inoculated on LB agar plates and cultured overnight at 37 °C. *C. albicans* was inoculated on sabouraud dextrose agar and cultured at 28 °C for 24 h. Single colonies were picked into Mueller-Hinton Broth for bacterial suspension and into RPMI 1640 media for fungal suspension and cultured overnight. The suspensions were adjusted to approximately 10⁶ and 10⁴ CFU/mL for bacteria and fungus, respectively. Each compound (2 μ L), serially diluted 2-fold in DMSO, was added into each row of a 96-well microplate containing 78 μ L of bacterial or fungal suspension per well. Vancomycin and ciprofloxacin (Solarbio, Beijing, China) were used as the positive control for *C. albicans*. DMSO was used as the negative control. The plates were cultured aerobically at 37 °C for 18 h for bacteria and at 35 °C

for 24 h for *C. albicans*. The Minimum Inhibitory Concentration (MIC) was defined as the lowest concentration of the compound at which no visible microbial growth was observed based on the standard set by the Clinical and Laboratory Standards Institute (CLSI).

3. Results and Discussion

3.1. Phylogenetic Analysis

The phylogenetic tree of BTBU20220155 constructed according to the ITS rDNA sequences is shown in Figure 1. The strain BTBU20220155 exhibited the highest identity (99.81%) with *A. insuetus* NRRL 279. Phylogenetically, the strain BTBU20220155 was identified as *A. insuetus*.




Figure 1. Maximum likelihood analysis based on ITS sequence. Bootstrap values \geq 50% are indicated at the nodes. The tree was rooted to *Penicillium. ubiquetum* CBS 126437.

3.2. Structure Elucidation

Asperinsuterpene A (compound 1) was obtained as a colorless, amorphous powder. The molecular formula of compound 1 was determined to be $C_{26}H_{32}O_6$ by HRESIMS, with m/z 441.2273 [M + H]⁺ (calcd. for C₂₆H₃₃O₆ 441.2272, Δ mmu + 0.1) (Figure S1), accounting for eleven degrees of unsaturation. The ¹H, ¹³C (Table 1) and HSQC NMR spectra (Figures S2-S4 in Supplementary Materials) revealed the presence of three carbonyl carbons, five olefinic quaternary carbons, three sp²-hybridized methines, three sp³-hybridized methylenes, two sp³-hybridized methines, three sp³-hybridized quaternary carbons (two oxygenated), and seven methyl groups (including one methyl doublet, one methoxy group and five methyl singlets). These functional groups accounted for seven of the eleven degrees of unsaturation, which indicated that compound 1 was tetracyclic. Ring A was established as a seven-membered unsaturated lactone based on the $^{1}H^{-1}H$ COSY correlations (Figure 2) between H-1 ($\delta_{\rm H}$ 6.32, d, J = 13.0 Hz) and H-2 ($\delta_{\rm H}$ 5.90, d, J = 13.0 Hz), and the HMBC correlations from H-1 to C-3 (δ_C 166.0), C-5 (δ_C 51.5), and C-10 (δ_C 51.5), and from H₃-25 $(\delta_H 1.41, s)$ and H₃-26 $(\delta_H 1.50, s)$ to C-4 $(\delta_C 84.3)$ and C-5. The mutual correlations between C-25 and the C-26 methyl singlets further supported this structure. The ¹H–¹H COSY correlations from H-5 ($\delta_{\rm H}$ 2.16, dd, J = 8.5, 6.5 Hz) to H₃-24 ($\delta_{\rm H}$ 1.22, d, J = 8.5 Hz) through the H₂-6 ($\delta_{\rm H}$ 1.83, m), H₂-7 ($\delta_{\rm H}$ 1.91, m; 1.73, m), and H₂-8 ($\delta_{\rm H}$ 2.12, m) correlations, the HMBC correlations from H₃-23 ($\delta_{\rm H}$ 1.57, s) to C-5, C-9 ($\delta_{\rm C}$ 92.8) and C-10, as well as those from H₃-24 to C-8 (δ_C 39.0) and C-9 revealed the presence of a cyclohexane ring B. Ring C was established to be a dihydrofuran moiety based on the HMBC correlations (Figure 2) from H-11 α to C-9, C-12 (δ_C 141.8), and C-18 (δ_C 163.5), as well as from H-11 β to C-12 and C-18. The tropone ring D was indicated by the HMBC correlations from H-13 ($\delta_{\rm H}$ 6.87, brs)

to C-15 ($\delta_{\rm C}$ 143.6), C-18 ($\delta_{\rm C}$ 163.5) and C-19 ($\delta_{\rm C}$ 23.9), from H₃-19 ($\delta_{\rm H}$ 2.14, s) to C-13 ($\delta_{\rm C}$ 131.2), C-14 ($\delta_{\rm C}$ 139.8) and C-15, and from H₃-22 ($\delta_{\rm H}$ 2.13, s) to C-16 ($\delta_{\rm C}$ 181.3), C-17 ($\delta_{\rm C}$ 127.8) and C-18. These HMBC correlations indicated the presence of a pentasubstituted 2,4,6 cycloheptatriene-1-one ring.




Figure 2. Key COSY, HMBC, and ROESY correlations in compounds 1 and 2.

The carbomethoxy group was defined based on the chemical shifts in C-20 ($\delta_{\rm C}$ 169.2), H₃-21 ($\delta_{\rm H}$ 3.78, s) and C-21 ($\delta_{\rm C}$ 52.0), and the HMBC correlation from H₃-21 to C-20. The weak HMBC correlation from H₃-19 to C-20 revealed the connection of C-15 and C-20. Rings A and B were combined according to the HMBC correlations from H₃-23 to C-1, C-5, C-9, and C-10. The linkage of rings B and C through a spiro carbon (C-9) was revealed by the HMBC correlations from H-11 α to C-8, C-9, and C-10. Additionally, the HMBC correlations from H-11 α and H-11 β to C-12, C-13, and C-18 indicated the combination of rings C and D. The relative stereochemistry of compound 1 was determined by ROESY spectra. The ROESY correlation between H-11 α ($\delta_{\rm H}$ 3.31) and H-1 ($\delta_{\rm H}$ 6.32) revealed the *cis*-form of C-11 and C-1. The ROESY correlation between H_3 -23 and H_3 -24 revealed that these two methyl groups were on the same side of ring B. The ROESY correlations (Figures 2 and S7) between H-5 and H₂-11 suggested that they are on the same side of ring B. The *cis*-form of H-5 and H_3 -25 was determined by the ROESY correlation from H-5 to H_3 -25. Therefore, the planar structure of compound 1 was determined. By comparing the calculated and experimental ECD spectra (Figure 3), the absolute configuration of compound 1 was determined to be 5R, 8S, 9S, 10S.

Asperinsuterpene B (compound **2**) was obtained as a colorless, amorphous powder. The molecular formula of compound **2** was determined as $C_{27}H_{38}O_7$ by HRESIMS with an m/z of 497.2518 [M + Na]⁺ (calcd. for $C_{27}H_{38}O_7$ Na 497.2510, Δ mmu + 0.8) (Figure S8), accounting for nine degrees of unsaturation. A comparison of the ¹H and ¹³C NMR data (Table 1, Figures S9 and S10) with those of compound **1** showed very similar chemical shifts, except for a saturated sidechain (δ_H 2.07, 2.00, m/ δ_H 35.2; δ_H 2.44/ δ_C 30.3), an additional methoxy group (δ_H 3.59, s/ δ_C 51.6), as well as an extra hydroxyl group at δ_H 3.45. These data revealed that compound **2** is a ring A hydrolyzed methyl ester derivative of compound **1**. Detailed HMBC correlations (Figures 2 and S13), particularly from 4-OH (δ_H 3.45) to C-4 (δ_C 74.8), C-25 (δ_C 28.9), and C-26 (δ_C 34.5), and from H₃-27 to C-3 (δ_C

174.6), supported the proposed assignment of the planar structure of compound **2**. The ROESY correlations between H-5 ($\delta_{\rm H}$ 1.73, m) and H₂-2 ($\delta_{\rm H}$ 2.44, m), and between H-11 α ($\delta_{\rm H}$ 3.62) and H₃-23 ($\delta_{\rm H}$ 1.25), indicated that they are on the same side of the cyclohexane ring, respectively. The upward equatorial methyl group of C-24 was confirmed by the ROESY correlations (Figures 2 and S14) from H-11 β ($\delta_{\rm H}$ 3.20) to H₃-24 ($\delta_{\rm H}$ 0.88). The optical rotation of compound **2** showed the same orientation as that of compound **1**, so the absolute configuration of compound **2** was determined as 5*R*, 8*S*, 9*S*, 10*S*.




Figure 3. The experimental and calculated ECD spectra of compound 1.

Asperinsuterpene C (compound 3) was obtained as a colorless, amorphous powder. The molecular formula of compound **3** was determined to be $C_{26}H_{36}O_6$ by HRESIMS, with an m/z of 445.2583 [M + H]⁺ (calcd. for C₂₆H₃₇O₆ 445.2585, Δ mmu—0.2) (Figure S15 in Supplementary Materials), accounting for nine degrees of unsaturation. A comparison of the ¹H and ¹³C NMR data (Table 2, Figures S16 and S17) with those of compound 1 revealed several similarities, but also significant differences. Compound 3 contained four olefinic carbons instead of eight. Two olefinic carbons in compound 1 were replaced by one methyl singlet and one more sp³-hybridized quaternary carbon in compound **3**. The other two olefinic carbons in compound 1 were replaced by two sp^3 methylenes. This suggested the absence of a tropone ring in compound 3. In the HMBC spectrum (Figures 4 and S20), the correlations from H₃-18 ($\delta_{\rm H}$ 1.60, s) to C-12 ($\delta_{\rm C}$ 48.8), C-13 ($\delta_{\rm C}$ 156.1) and C-17 ($\delta_{\rm C}$ 179.8), from H₃-19 ($\delta_{\rm H}$ 2.05, s) to C-12, C-13 and C-15 ($\delta_{\rm C}$ 184.2), as well as from H₃-22 ($\delta_{\rm H}$ 1.75, s) to C-15, C-16 (δ_C 108.8) and C-17 indicated the presence of a 2,5-cyclohexadiene-1-one ring in compound 3. The HMBC correlations from H_3 -19 to C-20 (δ_C 168.1) and from H_3 -21 $(\delta_{\rm H} 3.74, {\rm s})$ to C-20 revealed the attachment of a carbomethoxy group to C-14. The relative stereochemistry of compound 3 was determined by a detailed analysis of the ROESY data (Figures 4 and S21). The correlations from H-11 α ($\delta_{\rm H}$ 2.35) to H₃-18 ($\delta_{\rm H}$ 1.60s) and H₂-1 ($\delta_{\rm H}$ 1.91 and 1.82) indicated the *cis*-form of H-11 α to H₃-18. The ROESY correlation between H₃-23 ($\delta_{\rm H}$ 1.39) and H₃-24 ($\delta_{\rm H}$ 0.94) indicated that they were upward axial methyl groups. The correlation from H₃-25 ($\delta_{\rm H}$ 1.45, s) to H-5 ($\delta_{\rm H}$ 2.07, m) defined the positions of H₃-25 and H₃-26 ($\delta_{\rm H}$ 1.42, s). The calculated ECD spectrum (Figure 5) of the 5*R*, 8*S*, 9*S*, 10*S*, 12*R* configuration for compound 3 was consistent with the experimental data. Therefore, the structure of compound 3 was determined.

By comparing the NMR data (Tables S1–S7), the known compounds were identified as asnovolin I (4) [20], (2'E,4'E,6'E)-6-(1'-carboxyocta-2',4',6'-triene)-9-hydroxydrim-7-ene-11,12-olide (5), (2'E,4'E,6'E)-6-(1'-carboxyocta-2',4',6'-triene)-11,12-epoxy-9,11-dihydroxydrim-7-ene (6) [12], cinereain (7) [13], carnequinazolines A and B (8 and 9), carnemycin B (10) [14], and stromemycin (11) [16].




Figure 4. Key COSY, HMBC, and ROESY correlations in compound 3.




Figure 5. The calculated and experimental ECD spectra of compound 3.

3.3. Antimicrobial Activities of the Isolated Compounds

The antimicrobial activities of the isolated compounds were tested against *C. albicans*, *S. aureus*, and *E. col*. None of the tested compounds displayed antibacterial activity against *S. aureus and E. coli* (the MICs for vancomycin and ciprofloxacin were 1 and 0.03125 μ g/mL, respectively.). However, compounds **5** and **11** showed antifungal activity against *C. albicans*, with MIC values of 12.5 and 25 μ g/mL, respectively. Compound **5** has been identified from *Aspergillus* spp. isolated from marine and desert environments. It showed cytotoxic activity against L5178Y, HeLa, and PC12 cell lines [21], and endothelin receptor-binding inhibitory activity [12]. But compound **5** did not inhibit the growth of phytopathogenic *Fusarium oxysporum*, *F. graminearum*, *Colletotrichum musae*, and *C. gloeosporioides* [6]. Compound **11**, inhibiting the growth of *Ralstonia solanacearum* and *Bacillus subtilis*, has been identified in *Emericella variecolor* [16] and *A. ustus* [22,23]. Although these compounds showed weaker antifungal activity compared to amphotericin B (MIC = 0.5 μ g/mL), this is the first report of antifungal activity for compounds **5** and **11**.

4. Conclusions

Fungi have been proven to be important sources for the discovery of new structures and bioactive compounds. In our continuous screening program, which aims to discover novel compounds from fungi, a strain of *A. insuetus* was isolated from a soil sample collected from Sejila Mountain, Tibet, China. To date, only six papers have reported the chemical investigation of *A. insuetus* strains. To explore the chemical diversity of *A. insuetus*, we

performed a scale-up fermentation and chemical investigation of *A. insuetus* BTBU20220155. This led to the characterization of three new meroterpenoids, asperinsuterpenes A–C (compounds **1–3**), along with eight previously reported natural products (compounds **4–11**, Figure 6).




Figure 6. Structures of compounds 1–11.

The planar structures and relative configurations of the new compounds were confirmed by detailed analyses of the HRESIMS, 1D and 2D NMR spectroscopic data. Furthermore, the absolute configurations were determined via a comparison of the calculated and experimental electronic circular dichroism (ECD) spectra. Compounds 1 and 2 possess the carbon skeleton of tropolactone analogues, which have been found in a marine-derived fungus isolated from a sponge sample collected 40 feet from Manele Bay, Lanai, Hawaii [24]. However, the ring system in compounds 1 and 2, originally cyclohexane-tetrahydropyran, was rearranged into a spiro-cyclohexane-dihydrofuran. The carbon skeleton of compound 3 is similar to that of the asnovolins identified from *A. novofumigatus* [25].

Compounds **5** and **11** demonstrated antifungal activity against *C. albicans*. The antifungal activities of these compounds underscore the potential use of *A. insuetus* as a source of bioactive compounds with therapeutic applications. The specific mechanisms through which these compounds exert their antifungal effects could be the subject of further studies, including detailed biochemical assays and molecular docking studies to identify potential targets within fungal cells.

These findings contribute to the growing body of research on fungal metabolites and their potential uses in developing new antifungal therapies, particularly in an era in which resistance to existing antifungal drugs is becoming increasingly problematic.

Supplementary Materials: The following supporting information can be downloaded at: https: //www.mdpi.com/article/10.3390/jof10090611/s1, Figures S1–S7: HRESIMS, ¹H, ¹³C, HSQC, ¹H– ¹H COSY, HMBC, and ROESY spectra for compound **1**; Figures S8–S14: HRESIMS, ¹H, ¹³C, HSQC, ¹H–¹H COSY, HMBC, and ROESY spectra for compound **2**; Figures S15–S21: HRESIMS, ¹H, ¹³C, HSQC, ¹H–¹H COSY, HMBC, and ROESY spectra for compound **3**. Tables S1–S7: ¹³C NMR data for compounds **3–11**. **Author Contributions:** Conceptualization, X.Z. and F.S.; methodology, J.H. and X.Z.; validation, X.Z. and J.H.; formal analysis, F.S.; investigation, X.Z. and J.H.; resources L.W.; data curation, J.H.; writing—original draft preparation, X.X. and J.H.; writing—review and editing, X.X., L.M. and F.S.; supervision, F.S.; project administration, F.S.; funding acquisition, X.X. All authors have read and agreed to the published version of the manuscript.

Funding: This work was funded by grants from the Guangxi Key Laboratory of Beibu Gulf Marine Resources, Environment and Sustainable Development (MRESD-2023-C02), the National Natural Science Foundation of China (31960013), and the 5th batch of Tibet Agriculture & Animal Husbandry University Talents program.

Data Availability Statement: The original contributions presented in the study are included in the article/Supplementary Materials, further inquiries can be directed to the corresponding author.

Conflicts of Interest: The authors declare no conflicts of interest.

References

- 1. Xu, K.; Yuan, X.L.; Li, C.; Li, X.D. Recent discovery of heterocyclic alkaloids from marine-derived *Aspergillus* Species. *Mar. Drugs* **2020**, *18*, 54. [CrossRef]
- Sun, L.X.; Wang, H.N.; Yan, M.C.; Sai, C.M.; Zhang, Z. Research advances of bioactive sesquiterpenoids isolated from marinederived *Aspergillus* sp. *Molecules* 2022, 27, 7376. [CrossRef] [PubMed]
- 3. Bai, X.L.; Sheng, Y.; Tang, Z.X.; Pan, J.Y.; Wang, S.G.; Tang, B.; Zhou, T.; Shi, L.E.; Zhang, H.W. Polyketides as secondary mMetabolites from the genus *Aspergillus*. *J. Fungi*. **2023**, *9*, 261. [CrossRef] [PubMed]
- 4. Asmaey, M.A. Unravelling the secrets of α-pyrones from *Aspergillus* Fungi: A comprehensive review of their natural sources, biosynthesis, and biological activities. *Chem. Biodivers.* **2023**, *20*, e202301185. [CrossRef]
- Houbraken, J.; Due, M.; Varga, J.; Meijer, M.; Frisvad, J.C.; Samson, R.A. Polyphasic taxonomy of *Aspergillus* section Usti. *Stud. Mycol.* 2007, 59, 107–128. [CrossRef] [PubMed]
- 6. Hu, Z.B.; Chen, J.J.; Liu, Q.Q.; Wu, Q.L.; Chen, S.H.; Wang, J.J.; Li, J.; Liu, L.; Gao, Z.Z. Cyclohexenone derivative and drimane sesquiterpenes from the seagrass-derived fungus *Aspergillus insuetus*. *Chem. Biodivers*. **2023**, *20*, e202300424. [CrossRef] [PubMed]
- 7. Chi, L.P.; Li, X.M.; Wan, Y.P.; Li, X.; Wang, B.G. Ophiobolin sesterterpenoids and farnesylated phthalide derivatives from the deep sea cold-seep-derived fungus *Aspergillus insuetus* SD-512. *J. Nat. Prod.* **2020**, *83*, 3652–3660. [CrossRef]
- Cohen, E.; Koch, L.; Thu, K.M.; Rahamim, Y.; Aluma, Y.; Ilan, M.; Yarden, O.; Carmeli, S. Novel terpenoids of the fungus *Aspergillus insuetus* isolated from the Mediterranean sponge *Psammocinia* sp collected along the coast of Israel. *Bioorg. Med. Chem.* 2011, 19, 6587–6593. [CrossRef]
- 9. López-Gresa, M.P.; Cabedo, N.; González-Mas, M.C.; Ciavatta, M.L.; Avila, C.; Primo, J. Terretonins E and F, inhibitors of the mitochondrial respiratory chain from the marine-derived fungus *Aspergillus insuetus*. J. Nat. Prod. 2009, 72, 1348–1351. [CrossRef]
- 10. Chi, L.P.; Li, X.M.; Wan, Y.P.; Li, Y.H.; Li, X.; Wang, B.G. Two new phenol derivatives from the cold seep-derived fungus *Aspergillus insuetus* SD-512. *Chem. Biodivers.* **2021**, *18*, 6. [CrossRef]
- 11. Chi, L.P.; Liu, D.; Li, X.M.; Wan, Y.P.; Wang, B.G.; Li, X. Aspertides A-E: Antimicrobial pentadepsipeptides with a unique p-methoxycinnamoyl amide group from the marine isolates *Aspergillus tamarii* MA-21 and *Aspergillus insuetus* SD-512. *J. Agric. Food Chem.* **2023**, *71*, 13316–13324. [CrossRef] [PubMed]
- 12. Hayes, M.A.; Wrigley, S.K.; Chetland, I.; Reynolds, E.E.; Ainsworth, A.M.; Renno, D.V.; Latif, M.A.; Cheng, X.M.; Hupe, D.J.; Charlton, P.; et al. Novel drimane sesquiterpene esters from *Aspergillus ustus* var. *pseudodeflectus* with endothelin receptor binding activity. *J. Antibiot.* **1996**, *49*, 505–512. [CrossRef]
- 13. Cutler, H.G.; Springer, J.P.; Arrendale, R.F.; Arison, B.H.; Cole, P.D.; Roberts, R.G. Cinereain: A novel metabolite with plant growth regulating properties from *Botrytis cinerea*. *Agric. Biol. Chem.* **1988**, *52*, 1725–1733. [CrossRef]
- 14. Zhuravleva, O.I.; Afiyatullov, S.S.; Denisenko, V.A.; Ermakova, S.P.; Slinkina, N.N.; Dmitrenok, P.S.; Kim, N.Y. Secondary metabolites from a marine-derived fungus *Aspergillus carneus* Blochwitz. *Phytochemistry* **2012**, *80*, 123–131. [CrossRef] [PubMed]
- 15. Hopmann, C.; Knauf, M.A.; Weithmann, K.; Wink, J. *Preparation of Stromemycins as Stromelysin Inhibitors*; Aventis Pharma Deutschland GmbH: Eiterfeld, Germany, 2001.
- 16. Bringmann, G.; Lang, G.; Steffens, S.; Günther, E.; Schaumann, K. Evariquinone, isoemericellin, and stromemycin from a sponge derived strain of the fungus *Emericella variecolor*. *Phytochemistry* **2003**, *63*, 437–443. [CrossRef] [PubMed]
- 17. Larkin, M.A.; Blackshields, G.; Brown, N.P.; Chenna, R.; McGettigan, P.A.; McWilliam, H.; Valentin, F.; Wallace, I.M.; Wilm, A.; Lopez, R.; et al. Clustal W and clustal X version 2.0. *Bioinformatics* **2007**, *23*, 2947–2948. [CrossRef]
- 18. Xu, X.; Dong, Y.; Yang, J.; Wang, L.; Ma, L.; Song, F.; Ma, X. Secondary metabolites from marine-derived fungus Penicillium rubens BTBU20213035. J. Fungi 2024, 10, 424. [CrossRef]
- 19. Frisch, M.J.; Trucks, G.W.; Schlegel, H.B.; Scuseria, G.E.; Robb, M.A.; Cheeseman, J.R.; Scalmani, G.; Barone, V.; Petersson, G.A.; Nakatsuji, H.; et al. *Gaussian 16, Revision A.03*; Gaussian Inc.: Wallingford, CT, USA, 2016.
- Ren, Z.; Yang, L.; Ma, Q.; Xie, Q.; Dai, H.; Sun, K.; Zhao, Y. Meroterpenoids and steroids from the marine-derived fungus *Trametes* sp. ZYX-Z-16. *Molecules* 2022, 27, 8782. [CrossRef]

- 21. Liu, H.; Edrada-Ebel, R.; Ebel, R.; Wang, Y.; Schulz, B.; Draeger, S.; Müller, W.E.G.; Wray, V.; Lin, W.; Proksch, P. Drimane sesquiterpenoids from the fungus *Aspergillus ustus* isolated from the marine sponge *Suberites domuncula*. *J. Nat. Prod.* 2009, 72, 1585–1588. [CrossRef]
- 22. Xue, J.; Guo, X.; Xu, G.; Chen, X.; Jiao, L.; Tang, X. Discovery, identification, and mode of action of phenolics from marine-derived fungus *Aspergillus ustus* as antibacterial wit agents. *J. Agric. Food Chem.* **2024**, *72*, 2989–2996. [CrossRef]
- Neuhaus, G.F.; Loesgen, S. Antibacterial drimane sesquiterpenes from *Aspergillus ustus*. J. Nat. Prod. 2020, 84, 37–45. [CrossRef] [PubMed]
- Cueto, M.; MacMillan, J.B.; Jensen, P.R.; Fenical, W. Tropolactones A-D, four meroterpenoids from a marine-derived fungus of the genus Aspergillus. Phytochemistry 2006, 67, 1826–1831. [CrossRef] [PubMed]
- Ishikawa, K.; Sato, F.; Itabashi, T.; Wachi, H.; Takeda, H.; Wakana, D.; Yaguchi, T.; Kawai, K.; Hosoe, T. Asnovolins A-G, spiromeroterpenoids isolated from the fungus *Aspergillus novofumigatus*, and suppression of fibronectin expression by asnovolin E. *J. Nat. Prod.* 2016, *79*, 2167–2174. [CrossRef] [PubMed]

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.